Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial

Leila E Mansoor, Quarraisha Abdool Karim, Kathryn T Mngadi, Sarah Dlamini, Carl Montague, Nelisiwe Nkomonde, Nomzamo Mvandaba, Cheryl Baxter, Tanuja N Gengiah, Natasha Samsunder, Halima Dawood, Anneke Grobler, Janet A Frohlich, Salim S Abdool Karim, Leila E Mansoor, Quarraisha Abdool Karim, Kathryn T Mngadi, Sarah Dlamini, Carl Montague, Nelisiwe Nkomonde, Nomzamo Mvandaba, Cheryl Baxter, Tanuja N Gengiah, Natasha Samsunder, Halima Dawood, Anneke Grobler, Janet A Frohlich, Salim S Abdool Karim

Abstract

Background: The Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004 trial demonstrated a 39% reduction in HIV infection, with a 54% HIV reduction in women who used tenofovir gel consistently. A confirmatory trial is expected to report results in early 2015. In the interim, we have a unique window of opportunity to prepare for and devise effective strategies for the future policy and programmatic scale-up of tenofovir gel provision. One approach is to integrate tenofovir gel provision into family planning (FP) services. The CAPRISA 008 implementation trial provides an opportunity to provide post-trial access to tenofovir gel while generating empiric evidence to assess whether integrating tenofovir gel provision into routine FP services can achieve similar levels of adherence as the CAPRISA 004 trial.

Methods/design: This is a two-arm, open-label, randomized controlled non-inferiority trial. A maximum of 700 sexually active, HIV-uninfected women aged 18 years and older who previously participated in an antiretroviral prevention study will be enrolled from an urban and rural site in KwaZulu-Natal, South Africa. The anticipated study duration is 30 months, with active accrual requiring approximately 12 months (following which an open cohort will be maintained) and follow-up continuing for approximately 18 months. At each of the two sites, eligible participants will be randomly assigned to receive tenofovir gel through either FP services (intervention arm) or through the CAPRISA research clinics (control arm). As part of the study intervention, a quality improvement approach will be used to assist the FP services to expand their current services to include tenofovir gel provision.

Discussion: This protocol aims to address an important implementation question on whether FP services are able to effectively incorporate tenofovir gel provision for this at-risk group of women in South Africa. Provision of tenofovir gel to the women from the CAPRISA 004 trial meets the ethical obligation for post-trial access, and helps identify a potential avenue for future scale-up of microbicides within the public health system of South Africa.

Trial registration: This trial was registered with the South Africa Department of Health (reference: DOH-27-0812-4129) and ClinicalTrials.gov (reference: NCT01691768) on 05 July 2012.

References

    1. UNAIDS, WHO . AIDS Epidemic Update. Geneva: Joint United Nations Programme on HIV/AIDS and World Health Organization; 2009.
    1. Pettifor AE, Rees HV, Kleinschmidt I, Steffenson AE, MacPhail C, Hlongwa-Madikizela L, Vermaak K, Padian NS. Young people’s sexual health in South Africa: HIV prevalence and sexual behaviors from a nationally representative household survey. AIDS. 2005;19:1525–1534. doi: 10.1097/01.aids.0000183129.16830.06.
    1. Shisana O, Rehle T, Simbayi LC, Zuma K, Jooste S, Pillay-van-Wyk V, Mbelle N, Van Zyl J, Parker W, Zungu NP, Pezi S. South African National HIV Prevalence, Incidence, Behaviour and Communication Survey 2008: A Turning Tide Among Teenagers? Cape Town: HSRC Press; 2009.
    1. Haynes BF, Shattock RJ. Critical issues in mucosal immunity for HIV-1 vaccine development. J Allergy Clin Immunol. 2008;122:3–9. doi: 10.1016/j.jaci.2008.03.036.
    1. Yeaman GR, Asin S, Weldon S, Demian DJ, Collins JE, Gonzalez JL, Wira CR, Fanger MW, Howell AL. Chemokine receptor expression in the human ectocervix: implications for infection by the human immunodeficiency virus-type I. Immunology. 2004;113:524–533. doi: 10.1111/j.1365-2567.2004.01990.x.
    1. Shattock RJ, Moore JP. Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol. 2003;1:25–34. doi: 10.1038/nrmicro729.
    1. Abdool Karim Q. Heterosexual transmission of HIV - the importance of a gendered perspective in HIV prevention. In: Abdool Karim SS, Abdool Karim Q, editors. HIV/AIDS in South Africa. Cape Town: Cambridge University Press; 2005. pp. 243–461.
    1. Gregson S, Nyamukapa CA, Garnett GP, Mason PR, Zhuwau T, Carael M, Chandiwana SK, Anderson RM. Sexual mixing patterns and sex-differentials in teenage exposure to HIV infection in rural Zimbabwe. Lancet. 2002;359:1896–1903. doi: 10.1016/S0140-6736(02)08780-9.
    1. Abdool Karim Q, Abdool Karim SS, Nkomokazi J. Sexual behaviour and knowledge of AIDS among urban black mothers. Implications for AIDS intervention programmes. S Afr Med J. 1991;80:340–343.
    1. Simbayi LC, Chauveau J, Shisana O. Behavioural responses of South African youth to the HIV/AIDS epidemic: a nationwide survey. AIDS Care. 2004;16:605–618. doi: 10.1080/09540120410001716405.
    1. Hoffman S, O’Sullivan LF, Harrison A, Dolezal C, Monroe-Wise A. HIV risk behaviors and the context of sexual coercion in young adults’ sexual interactions: results from a diary study in rural South Africa. Sex Transm Dis. 2006;33:52–58. doi: 10.1097/01.olq.0000187198.77612.d8.
    1. Jewkes RK, Levin JB, Penn-Kekana LA. Gender inequalities, intimate partner violence and HIV preventive practices: findings of a South African cross-sectional study. Soc Sci Med. 2003;56:125–134. doi: 10.1016/S0277-9536(02)00012-6.
    1. Gupta GR, Weiss E, Whelan D. Male-female inequalities result in submission to high-risk sex in many societies. Special report: women and HIV. AIDS Anal Afr. 1995;5:8–9.
    1. Stein ZA. HIV prevention: the need for methods women can use. Am J Public Health. 1990;80:460–462. doi: 10.2105/AJPH.80.4.460.
    1. Feldblum PJ, Adeiga A, Bakare R, Wevill S, Lendvay A, Obadaki F, Olayemi MO, Wang L, Nanda K, Rountree W. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One. 2008;3:e1474. doi: 10.1371/journal.pone.0001474.
    1. Richardson BA, Lavreys L, Martin HL, Jr, Stevens CE, Ngugi E, Mandaliya K, Bwayo J, Ndinya-Achola J, Kreiss JK. Evaluation of a low-dose nonoxynol-9 gel for the prevention of sexually transmitted diseases: a randomized clinical trial. Sex Transm Dis. 2001;28:394–400. doi: 10.1097/00007435-200107000-00006.
    1. Roddy RE, Zekeng L, Ryan KA, Tamoufe U, Tweedy KG. Effect of nonoxynol-9 gel on urogenital gonorrhea and chlamydial infection: a randomized controlled trial. JAMA. 2002;287:1117–1122. doi: 10.1001/jama.287.9.1117.
    1. van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, Sirivongrangson P, Abdool Karim SS, Mâsse B, Perriëns J, Laga M, COL-1492 Study Group Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 2002;360:971–977. doi: 10.1016/S0140-6736(02)11079-8.
    1. Van Damme L, Govinden R, Mirembe FM, Guedou F, Solomon S, Becker ML, Pradeep BS, Krishnan AK, Alary M, Pande B, Ramjee G, Deese J, Crucitti T, Taylor D. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med. 2008;359:463–472. doi: 10.1056/NEJMoa0707957.
    1. Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, Friedland B, Govender S, De Kock A, Cassim N, Palanee T, Dozier G, Maguire R, Lahteenmaki P. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1977–1987. doi: 10.1016/S0140-6736(08)61842-5.
    1. McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, Gafos M, Jentsch U, Pool R, Chisembele M, Kapiga S, Mutemwa R, Vallely A, Palanee T, Sookrajh Y, Lacey CJ, Darbyshire J, Grosskurth H, Profy A, Nunn A, Hayes R, Weber J. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet. 2010;376:1329–1337. doi: 10.1016/S0140-6736(10)61086-0.
    1. Abdool Karim SS, Richardson BA, Ramjee G, Hoffman IF, Chirenje ZM, Taha T, Kapina M, Maslankowski L, Coletti A, Profy A, Moench TR, Piwowar-Manning E, Masse B, Hillier SL, Soto-Torres L. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS. 2011;25:957–966. doi: 10.1097/QAD.0b013e32834541d9.
    1. Kreiss J, Ngugi E, Holmes K, Ndinya-Achola J, Waiyaki P, Roberts PL, Ruminjo I, Sajabi R, Kimata J, Fleming TR, Anzala A, Holton D, Plummer F. Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA. 1992;268:477–482. doi: 10.1001/jama.1992.03490040053025.
    1. Roddy RE, Zekeng L, Ryan KA, Tamoufe U, Weir SS, Wong EL. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med. 1998;339:504–510. doi: 10.1056/NEJM199808203390803.
    1. De Clercq E. Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge. Biochem Pharmacol. 2007;73:911–922. doi: 10.1016/j.bcp.2006.09.014.
    1. Rohan LC, Moncla BJ, Kunjara Na Ayudhya RP, Cost M, Huang Y, Gai F, Billitto N, Lynam JD, Pryke K, Graebing P, Hopkins N, Rooney JF, Friend D, Dezzutti CS. In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS One. 2010;5:e9310. doi: 10.1371/journal.pone.0009310.
    1. Sokal DC, Karim QA, Sibeko S, Yende-Zuma N, Mansoor LE, Baxter C, Grobler A, Frolich J, Kharsany AB, Omar Z, Miya N, Mlisana K, Maarshalk S, Karim SS. Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial. Antivir Ther. 2013;18(3):301–310. doi: 10.3851/IMP2311.
    1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany ABM, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D, on behalf of the CAPRISA 004 Trial Group Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168–1174. doi: 10.1126/science.1193748.
    1. Abdool Karim Q, Abdool Karim SS, on behalf of the CAPRISA 004 Trial Group . CAPRISA 004: Effectiveness & Safety of Vaginal Microbicide 1% Tenofovir Gel for Prevention of HIV Infection in Women. Vienna, Austria: XVIII International AIDS Conference; 2010.
    1. Williams BG, Abdool Karim SS, Gouws E, Abdool Karim Q. Potential Impact of Tenofovir Gel on the HIV Epidemic in South Africa. Vienna, Austria: XVIII International AIDS Conference; 2010.
    1. Glynn JR, Biraro S, Weiss HA. Herpes simplex virus type 2: a key role in HIV incidence. AIDS. 2009;23:1595–1598. doi: 10.1097/QAD.0b013e32832e15e8.
    1. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, Malahleha M, Owino F, Manongi R, Onyango J, Temu L, Monedi MC, Mak’Oketch P, Makanda M, Reblin I, Makatu SE, Saylor L, Kiernan H, Kirkendale S, Wong C, Grant R, Kashuba A, Nanda K, Mandala J, Fransen K, Deese J, Crucitti T, Mastro TD, Taylor D. Preexposure prophylaxis for HIV infection among African Women. N Engl J Med. 2012;367:411–422. doi: 10.1056/NEJMoa1202614.
    1. Marrazzo JRG, Nair G, Palanee T, Mkhize B, Nakabiito Taljaard M, Piper J, Gomez Feliciano K, Chirenje M. 20th CROI. Atlanta GA: Oral Abstract 26LB; 2013. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine or vaginal tenofovir gel in the VOICE study (MTN 003)
    1. Richardson WC, Berwick DM, Bisgard JC. The Institute of Medicine report on medical errors. N Engl J Med. 2000;343:663–664. doi: 10.1056/NEJM200008313430917.
    1. Berwick DM. Disseminating innovations in health care. JAMA. 2003;289:1969–1975. doi: 10.1001/jama.289.15.1969.
    1. Berwick DM. Continuous improvement as an ideal in health care. N Engl J Med. 1989;320:53–56. doi: 10.1056/NEJM198901053200110.
    1. Abdool Karim Q, Kharsany AB, Frohlich JA, Werner L, Mashego M, Mlotshwa M, Madlala BT, Ntombela F, Abdool Karim SS. Stabilizing HIV prevalence masks high HIV incidence rates amongst rural and urban women in KwaZulu-Natal, South Africa. Int J Epidemiol. 2011;40:922–930. doi: 10.1093/ije/dyq176.
    1. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41. doi: 10.1159/000180580.
    1. Schackman BR. Implementation science for the prevention and treatment of HIV/AIDS. J Acquir Immune Defic Syndr. 2010;55(Suppl 1):S27–S31. doi: 10.1097/QAI.0b013e3181f9c1da.
    1. Kiggundu V, Watya S, Kigozi G, Serwadda D, Nalugoda F, Buwembo D, Settuba A, Anyokorit M, Nkale J, Kighoma N, Ssempijja V, Wawer M, Gray RH. The number of procedures required to achieve optimal competency with male circumcision: findings from a randomized trial in Rakai, Uganda. BJU Int. 2009;104:529–532. doi: 10.1111/j.1464-410X.2009.08420.x.
    1. Herman-Roloff A, Llewellyn E, Obiero W, Agot K, Ndinya-Achola J, Muraguri N, Bailey RC. Implementing voluntary medical male circumcision for HIV prevention in Nyanza Province, Kenya: lessons learned during the first year. PLoS One. 2011;6:e18299. doi: 10.1371/journal.pone.0018299.
    1. Stringer EM, Ekouevi DK, Coetzee D, Tih PM, Creek TL, Stinson K, Giganti MJ, Welty TK, Chintu N, Chi BH, Wilfert CM, Shaffer N, Dabis F, Stringer JS, PEARL Study Team Coverage of nevirapine-based services to prevent mother-to-child HIV transmission in 4 African countries. JAMA. 2010;304:293–302. doi: 10.1001/jama.2010.990.
    1. Mate KS, Bennett B, Mphatswe W, Barker P, Rollins N. Challenges for routine health system data management in a large public programme to prevent mother-to-child HIV transmission in South Africa. PLoS One. 2009;4:e5483. doi: 10.1371/journal.pone.0005483.
    1. Zong Z. Should post-trial provision of beneficial experimental interventions be mandatory in developing countries? J Med Ethics. 2008;34:188–192. doi: 10.1136/jme.2006.018754.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit